Biogen Inc. (BIIB)
Nasdaq: BIIB · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 1996
Grade5.9
◀ Past 6.4● Present 6.7▶ Future 4.4
Who owns Biogen Inc.
As filed with the SECHolders of 5% or more
4
Fmr LLC holds 12.4% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 6, 2026 says.
Directors and officers
20
report now, of 48 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 11.3% in Jun 5, 2026
Primecap Management Co/ca/
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Nov 10, 2025 · COMMON STOCK · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What BIIB reports owning in othersstakes of 5% or more, and other ties
Apellis Pharmaceuticals, Inc.
SCHEDULE 13D/A · filed May 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%
Sage Therapeutics, Inc.
SCHEDULE 13D/A · filed Jul 30, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Other ties the annual report names
Human Immunology Biosciences
A company bought · acquisition · Jun 2024 · owns, named in the 10-K filed Feb 6, 2026
Reata Pharmaceuticals, Inc
A company bought · acquisition · Sep 2023 · owns, named in the 10-K filed Feb 6, 2026
Alcyone Therapeutics, Inc.
A company bought · asset acquisition · owns, named in the 10-K filed Feb 6, 2026
Hi-Bio Acquisition
A company bought · acquisition · owns, named in the 10-K filed Feb 6, 2026
91 subsidiaries in 44 countries, from the list filed with the 10-K filed Feb 6, 2026.
Insider tradesForm 4
4sales
1purchases
4sales on a scheduled plan
2people selling
$900,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 2, 2025 to Nov 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 48 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development | 2 | $700,000 | 2 | 0 | $0 |
| Minor Lloyd | director | 2 | $200,000 | 2 | 0 | $0 |
| Murphy Nicole | Head of Pharm Ops and Tech | 0 | $0 | 0 | 1 | $0 |